OAKLAND, Calif., Dec. 15, 2020 /PRNewswire/ -- Aditum Bio,
the biotech investment firm co-founded in 2019 by former Novartis
CEO Joe Jimenez and former President
of the Novartis Institutes for BioMedical Research (NIBR) Dr.
Mark Fishman, today announced the
formation of Anteris Bio, a portfolio company developing a new
therapy for the treatment of renal disease. Anteris Bio is being
formed following the successful in-licensing of ANT-401 from vTv
Therapeutics (NASDAQ:VTVT).
Anteris Bio is the third independent company launched by Aditum
Bio, whose mission is to give large patient populations access to
medicines which otherwise may not be developed. To speed these
drugs to market, Aditum Bio fosters an incubator model, focusing on
the translational phase of drug development. The "spin out" model
enables a nimble, start-up culture with its own dedicated team of
managers.
"We are excited to announce the formation of Anteris Bio, with
its focus on renal disease. Unmet medical need is high, with few
therapies in development that have the potential to be disease
modifying," said Joe Jimenez,
Co-Founder and Managing Director of Aditum Bio. Dr. Mark Fishman, Co-Founder and Chair of the
Medical and Scientific Advisory Boards added, "The relentless
progression of renal disease has been largely refractory to medical
therapies. We hope the fundamental mechanism exemplified by
ANT-401 will change that for the better."
Chronic kidney disease (CKD) is one of the most significant
global health challenges and a leading cause of mortality, both
directly and as a key risk factor for cardiovascular disease.
Globally, it is estimated that nearly 700 million individuals
suffer from CKD, and CKD is directly responsible for over 1 million
deaths annually. Clear unmet medical need exists in renal disease
as therapies have traditionally revolved around treatment of
symptoms (e.g. hypertension, renal failure). ANT-401 is a small
molecule activator of Nrf2, a mechanism which has disease modifying
potential across multiple etiologies of renal disease. Nrf2 is a
transcription factor required for the expression of many
antioxidant genes regulated by the ARE promoter sequence. ANT-401
activates Nrf2 through the inhibition of Bach1, a transcription
repressor that prevents Nrf2 activity in the nucleus.
Aditum Bio has partnered with TrialSpark, a technology driven
research company that can complete clinical trials faster and at a
lower cost than traditional trials. TrialSpark partners with
doctors to create trial and referral sites within their existing
practices. Their digital platform enables faster patient
recruitment, together with common data entry and analysis across
sites which leads to speed, quality, and standardization.
About Aditum Bio
Aditum Bio is committed to improving
public health by accelerating R&D in disease areas with both
large and more targeted patient populations, where medical
innovation can have a huge impact. Aditum Bio focuses on basic
mechanisms of disease, in-licenses promising drug candidates
directed at such pathophysiologies, and spins-out individual
companies dedicated to bringing each candidate through Phase II
clinical trials. In partnership with TrialSpark, Aditum Bio uses
data, software and technology to help bring innovative medicines
through the clinical trial phase more quickly and with lower costs
than traditional pharmaceutical companies.
For more information, please visit www.aditumbio.com.
About TrialSpark
TrialSpark is a technology company that runs end-to-end clinical
trials as an alternative to a traditional CRO. TrialSpark has built
a technology platform that optimizes all aspects of a clinical
trial, enabling faster trial completion, higher data quality, and a
more patient-centric experience. TrialSpark also empowers doctors
in the community setting to participate in clinical trials,
unlocking the 99% of patients the industry has traditionally
struggled to reach, accelerating recruitment rates, and
democratizing access to clinical trials. TrialSpark is backed by
leading investors such as Michael
Moritz, John Doerr, Thrive
Capital, and Sequoia Capital.
About vTv Therapeutics
vTv Therapeutics Inc. is a
clinical-stage biopharmaceutical company focused on developing oral
small molecule drug candidates. vTv has a pipeline of clinical drug
candidates led by programs for the treatment of type 1 diabetes,
Alzheimer's disease, and inflammatory disorders. vTv's development
partners are pursuing additional indications in type 2 diabetes,
chronic obstructive pulmonary disease (COPD), and genetic
mitochondrial diseases. For more information, please visit
www.vtvtherapeutics.com or follow us on Twitter:
@vTvTherapeutics.
Media
For inquiries, please contact:
Susie Phillips
Aditum Bio
(510) 227-2096
public.relations@aditumbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aditum-bio-announces-formation-of-third-company-anteris-bio-301193067.html
SOURCE Aditum Bio